CandlesenseCandlesense
News/Companies/CYCC

CYCC News

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

CYCC

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update.

August 13, 2025Earnings
Read more →

Cyclacel Reports $0.1M Q1 Loss, Refocuses On Oral Plogosertib And Seeks Strategic Options After UK Exit

CYCC

May 15, 2025
Read more →

Cyclacel Pharmaceuticals Announces Majority Stockholder And Board Approval Of Reverse Stock Split At A Ratio Between 1-For-3 And 1-For-100

CYCC

May 14, 2025
Read more →

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

CYCC

May 9, 2025
Read more →

Cyclacel Pharmaceuticals To Implement 1-For-16 Reverse Stock Split

CYCC

May 7, 2025
Read more →

Cyclacel Pharmaceuticals Enters Exchange Agreement To Make FITTERS' Subsidiary, Fitters Sdn. Bhd., Its Wholly-Owned subsidiary

CYCC

May 6, 2025
Read more →

Cyclacel Pharmaceuticals Has Been Granted European Patent Number EP4013503 Titled CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE (FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SUCH AS CANCER, LEUKAEMIA, AND LYMPHOMA).

CYCC

April 24, 2025
Read more →

Cyclacel Pharmaceuticals Announces $1M Private Placement Offering Of Convertible Series E Preferred Stock To Certain Accredited Investors

CYCC

March 24, 2025
Read more →

Cyclacel Pharmaceuticals Announces Leadership Change After $6.3M Share Purchase; Datuk Dr. Doris Wong Sing Ee Acquires 70% Stake And Becomes CEO; David Lazar Resigns As Interim CEO, Kiu Cu Seng Appointed CFO

CYCC

February 27, 2025
Read more →